We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email :PharmaSources@imsinoexpo.com
Whatsapp :+86-13621645194
Category:Active Pharmaceutical Ingredients > Other Active Pharmaceutical Ingredients Product Name:Ganirelix CAS No.:123246-29-7 Standard:ChP, USP, EP Price(USD):Negotiable Company:HYBIO PHARMACEUTICAL CO., LTD.
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Asia,Middle East
Sample Provided: no
Payment Terms: T/T
Indications:
Prevention of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation in assisted reproductive technologies (ART) like in-vitro fertilization (IVF).
Mechanism of Action: Ganirelix works by competitively blocking the GnRH receptors on the pituitary gland, thus preventing the release of LH and follicle-stimulating hormone (FSH). This inhibition prevents premature ovulation, allowing for more controlled ovarian hyperstimulation.
Pharmacokinetics:
Absorption: Rapidly and almost completely absorbed after subcutaneous administration.
Distribution: Rapidly distributed in the body.
Metabolism: Mainly hepatic.
Excretion: Primarily through the kidneys.
Form: Ganirelix API is typically presented as a white to off-white lyophilized powder.